Amarantus Bioscience Holdings Inc (AMBS)

[JPetroInc]

Under the terms of the Agreement:

http://investor.generex.com/releasedetail.cfm?ReleaseID=583583

"Generex will grant to Amarantus an exclusive worldwide license for the clinical & regulatory development and commercialization of Generex's proprietary RapidMist™ technologies in connection with any and all therapeutic applications of MANF technologies developed by Amarantus in all fields except the treatment of diabetes".

Note the word "except". Now, note this statement:

"This special property has been scientifically demonstrated in various pre-clinical models of human disease, indicating that MANF-based products could have a significant impact on the treatment of a myriad of human diseases as first-in-class treatments".

So now - read this part:

"Additionally, our diabetes collaboration with Amarantus will afford us an opportunity to expand the Generex pipeline in the diabetes space".

AMBS wanted the RapidMist™ delivery system. Generex wanted MANF for diabetes. During this time, something interesting was discovered and it is already in works that no one knew about. Welcome to where we are today as Mart Saarma validates MANF for diabetes - not his first time working with MANF by the way. The diabetes focus will make a lot of sense very soon.

http://onlineapps.jdfcure.org/AbstractReport.cfm?grant_id=39181&abs_type=LAY

Project Title

A Novel ER Stress Regulating Growth Factor for the Treatment of Diabetes

Objective

Potent and specific strategies for type 1 diabetes (T1D) prevention and treatment are urgently needed. This is a pre-clinical translational project designed to explore innovative therapeutic interventions using novel growth factor MANF for T1D. In T1D beta cells die and MANF can prevent their death and stimulate their proliferation. In vitro studies on primary mouse and human islet cells, new knockout and transgenic mice and mouse models of T1D will be used to collect data on the mode of action and therapeutic efficacy of MANF. It is a collaborative project between two laboratories having expertise in growth factors, cellular and animal models of T1D.

Watsonhelper